Invasive intraductal papillary mucinous neoplasm: Predictors of survival and role of adjuvant therapy

HPB

Volumn 12, Issue 7, 2010, Pages 447-455

  Turrini, Olivier ^a   Waters, Joshua A ^a   Schnelldorfer, Thomas ^b   Lillemoe, Keith D ^a   Yiannoutsos, Constantin T ^c   Farnell, Michael B ^b   Sarr, Michael G ^b   Schmidt, C Max ^a,d  

^a INDIANA UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d 357 Med Res and Libary Building   (United States)

Author keywords

Adjuvant treatment; Intraductal papillary mucinous neoplasm; Invasive

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GEMCITABINE;

ADJUVANT THERAPY; AGED; ARTICLE; ASPIRATION BIOPSY; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PANCREAS; PANCREAS BIOPSY; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 77956904816     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00196.x     Document Type: Article

References (22)

1. Ohashi K, Murakami Y, Maruyama M, Takokochi T, Ohta H, Ohashi I. (1982) Four cases of 'mucin-producing' cancer of the pancreas on specific findings of the papilla of Vater. Prog Dig Endosc 20:348-351.
2. Kloeppel G, Solcia E, Longnecker DS, Capella C, Sobin LH. (1996) Histological typing of tumours of the exocrine pancreas. In: Kloeppel G. World Health Organization International Histological Classification of Tumours, 2nd edn. Berlin: Springer, pp. 1-60.
3. Waters JA, Schmidt CM. (2008) Intraductal papillary mucinous neoplasm - when to resect? Adv Surg 42:87-108.
4. Poultsides GA, Reddy S, Cameron JL, Hruban RH, Pawlik TM, Ahuja N et al. (2010) Histopathologic basis for the favourable survival after resection of intraductal papillary mucinous neoplasm-associated invasive adenocarcinoma of the pancreas. Ann Surg 251:470-476.
5. Traverso LW. (2006) Pancreatic cancer: Surgery alone is not sufficient. Surg Endosc 20 (Suppl. 2):446-449.
6. Murakami Y, Uemura K, Ohge H, Hayashidani Y, Sudo T, Sueda T. (2006) Intraductal papillary-mucinous neoplasms and mucinous cystic neoplasms of the pancreas differentiated by ovarian-type stroma. Surgery 140:448-453.
7. Longnecker DS, Adler G, Hruban RH et al. (2000) Intraductal papillary mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press, pp. 237- 241.
8. House MG, Gönen M, Jarnagin WR, D'Angelica M, DeMatteo RP, Fong Y et al. (2007) Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 11:1549-1555.
9. Bilimoria KY, Talamonti MS, Sener SF, Bilimoria MM, Stewart AK, Winchester DP et al. (2008) Effect of hospital volume on margin status after pancreaticoduodenectomy for cancer. J Am Coll Surg 207:510-519.
10. Van Roest MH, Gouw AS, Peeters PM, Porte RJ, Slooff MJ, Fidler V et al. (2008) Results of pancreaticoduodenectomy in patients with periampullary adenocarcinoma: Perineural growth more important prognostic factor than tumour localization. Ann Surg 248:97-103.
11. Walsh RM, Vogt DP, Henderson JM, Hirose K, Mason T, Bencsath K et al. (2008) Management of suspected pancreatic cystic neoplasms based on cyst size. Surgery 144:677-684.
12. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M et al. (2007) Intraductal papillary mucinous neoplasms: Predictors of malignant and invasive pathology. Ann Surg 246:644-651.
13. D'Angelica M, Brennan MF, Suriawinata AA, Klimstra D, Conlon KC. (2004) Intraductal papillary mucinous neoplasms of the pancreas: An analysis of clinicopathologic features and outcome. Ann Surg 239:400-408.
14. Nara S, Shimada K, Kosuge T, Kanai Y, Hiraoka N. (2008) Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: Clinicopathologic study of 104 intraductal papillary-mucinous neoplasms. Am J Surg Pathol 32:243-255.
15. Wada K, Kozarek RA, Traverso LW. (2005) Outcomes following resection of invasive and non-invasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg 189:632-636.
16. Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA et al. (2009) Longterm survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol 16:836-847.
17. Adsay NV, Conlon KC, Zee SY, Brennan MF, Klimstra DS. (2002) Intraductal papillary-mucinous neoplasms of the pancreas: An analysis of in situ and invasive carcinomas in 28 patients. Cancer 94:62-77.
18. Muscari F, Suc B, Kirzin S, Hay JM, Fourtanier G, Fingerhut A et al. (2006) Risk factors for mortality and intra-abdominal complications after pancreatoduodenectomy: Multivariate analysis in 300 patients. French Association for Surgical Research. Surgery 139:591-598.
19. Aloia TE, Lee JE, Vauthey JN, Abdalla EK, Wolff RA, Varadhachary GR et al. (2007) Delayed recovery after pancreaticoduodenectomy: A major factor impairing the delivery of adjuvant therapy? J Am Coll Surg 204:347-355.
20. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K et al. (2007) Adjuvant chemotherapy with gemcitabine vs. observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297:267-277.
21. Neoptolemos JP, Stocken DD, Tudur Smith C, Bassi C, Ghaneh P, Owen E et al. (2009) Büchler MW Adjuvant 5-fluorouracil and folinic acid vs. observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 100:246-250.
22. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. (2009) Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. Eur J Surg Oncol 35:600-604